4,550 Shares in Illumina, Inc. $ILMN Bought by SYM FINANCIAL Corp

SYM FINANCIAL Corp bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,550 shares of the life sciences company’s stock, valued at approximately $434,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Rise Advisors LLC boosted its position in shares of Illumina by 173.6% during the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 224 shares in the last quarter. Cullen Frost Bankers Inc. bought a new position in Illumina in the second quarter worth approximately $41,000. Golden State Wealth Management LLC boosted its holdings in Illumina by 123.2% in the first quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company’s stock worth $42,000 after acquiring an additional 292 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Illumina by 2,936.8% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock worth $46,000 after purchasing an additional 558 shares in the last quarter. Finally, Blue Trust Inc. lifted its holdings in shares of Illumina by 63.1% in the 2nd quarter. Blue Trust Inc. now owns 654 shares of the life sciences company’s stock worth $62,000 after purchasing an additional 253 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Stephens set a $110.00 target price on Illumina and gave the stock an “overweight” rating in a report on Monday, August 4th. Morgan Stanley raised their price objective on shares of Illumina from $100.00 to $105.00 and gave the company an “equal weight” rating in a research note on Monday, August 4th. Daiwa Capital Markets lowered shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price objective on the stock. in a research note on Tuesday, August 12th. Barclays raised their price target on shares of Illumina from $90.00 to $95.00 and gave the company an “underweight” rating in a research report on Thursday, October 2nd. Finally, Scotiabank cut shares of Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price target on the stock. in a research report on Friday, July 11th. Five research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $115.25.

Illumina Stock Up 0.2%

ILMN opened at $100.35 on Tuesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The company’s 50-day moving average is $98.17 and its 200 day moving average is $91.92. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The firm has a market capitalization of $15.42 billion, a P/E ratio of 12.70, a PEG ratio of 2.47 and a beta of 1.40.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter last year, the firm earned $0.36 EPS. The company’s quarterly revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.